Practicalities of Drugging the Phosphatidylinositol-3-Kinase/Akt Cell Survival Signaling Pathway

This publication has 21 references indexed in Scilit:

• Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
  Nature Reviews Drug Discovery, 2005
• The Akt/PKB pathway: molecular target for cancer drug discovery
  Oncogene, 2005
• The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts
  Molecular Cancer Therapeutics, 2005
• Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo
  Molecular Cancer Therapeutics, 2005
• Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
  Clinical Cancer Research, 2005
• 7-Hydroxystaurosporine (UCN-01) Inhibition of Akt Thr308 but not Ser473 Phosphorylation
  Clinical Cancer Research, 2004
• 94 The cytotoxic effects of 17-AAG, an inhibitor of Hsp90 are enhanced by combination with the PI-3-kinase inhibitor LY294002 in non-small cell lung cancer (NSCLC) cell lines
  European Journal of Cancer Supplements, 2004
• A Specific Antagonist of the p110δ Catalytic Component of Phosphatidylinositol 3′-Kinase, IC486068, Enhances Radiation-Induced Tumor Vascular Destruction
  Cancer Research, 2004
• Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
  Journal of Clinical Oncology, 2004
• The v-Crk Oncogene Enhances Cell Survival and Induces Activation of Protein Kinase B/Akt
  Published by Elsevier ,2001